Abstract
Psoriatic arthritis (PsA) is a chronic inflammatory, autoimmune disease with heterogeneous manifestations. PsA does not exclusively affect the locomotor apparatus but skin affection and other organ manifestations are usually present as well.
For quite some time, PsA therapy was restricted to nonsteroidal anti-inflammatory drugs, disease-modifying drugs, and still more rarely glucocorticoids. Over the last decades the situation has gradually changed with the arrival of biological treatment.
The biological agent group longest in use and already established are tumour necrosis factor-a inhibitors, gradually followed by selective inhibitors of other inflammatory cytokines (interleukin-12 and interleukin-23).The so-called "small molecules" are an autonomous group of agents able to inhibit transduction signals. A member of this group is also apremilast, already approved for PsA therapy, but still not reimbursed in the CR.